Vasodilators for inhospital heart failure management: a rapid review (update)
Schaink A, Lambrinos A
Record ID 32015000503
English
Authors' recommendations:
The following conclusions were drawn from the examination of 1 RCT comparing nesiritide versus nitroglycerin as part of the addendum to the rapid review:
Based on moderate quality of evidence, there was no statistically significant difference in renal function biomarkers (at baseline, 24 hours, 48 hours, and discharge) among patients who received nesiritide versus nitroglycerin.
Based on low quality of evidence, there was no statistically significant difference in mortality (at 3 or 6 months post-discharge) among patients who received nesiritide versus nitroglycerin.
Details
Project Status:
Completed
Year Published:
2015
URL for published report:
http://www.hqontario.ca/Portals/0/Documents/eds/rapid-reviews/qbp-chf-vasodilators-20150209-en.pdf
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Canada
MeSH Terms
- Humans
- Heart Failure
- Vasodilator Agents
- Natriuretic Peptide, Brain
- Nitroglycerin
- Inpatients
Contact
Organisation Name:
Health Quality Ontario
Contact Address:
Evidence Development and Standards, Health Quality Ontario, 130 Bloor Street West, 10th floor, Toronto, Ontario Canada M5S 1N5
Contact Name:
EDSinfo@hqontario.ca
Contact Email:
OH-HQO_hta-reg@ontariohealth.ca
Copyright:
Health Quality Ontario
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.